1. Search Result
Search Result
Results for "

fibrinogen-

" in MedChemExpress (MCE) Product Catalog:

73

Inhibitors & Agonists

1

Screening Libraries

6

Biochemical Assay Reagents

33

Peptides

4

Inhibitory Antibodies

3

Natural
Products

31

Recombinant Proteins

1

Isotope-Labeled Compounds

12

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125864
    Fibrinogen (Bovine)
    2 Publications Verification

    Interleukin Related NF-κB Inflammation/Immunology
    Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
    Fibrinogen (Bovine)
  • HY-P1929
    Bivalirudin
    Maximum Cited Publications
    9 Publications Verification

    Thrombin Interleukin Related RSV Infection Cardiovascular Disease Inflammation/Immunology
    Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .
    Bivalirudin
  • HY-17369B
    Tirofiban
    5+ Cited Publications

    L700462; MK383

    Integrin Cardiovascular Disease
    Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban
  • HY-17369

    L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate

    Integrin Cardiovascular Disease
    Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban hydrochloride monohydrate
  • HY-123275A
    H-D-Phe-Pip-Arg-pNA hydrochloride
    1 Publications Verification

    S-2238 hydrochloride

    Fluorescent Dye Others
    H-D-Phe-Pip-Arg-pNA (S-2238) hydrochloride, a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA hydrochloride is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA hydrochloride is sensitive, accurate, and easy to perform .
    H-D-Phe-Pip-Arg-pNA hydrochloride
  • HY-123275B
    H-D-Phe-Pip-Arg-pNA acetate
    1 Publications Verification

    S-2238 acetate

    Fluorescent Dye Others
    H-D-Phe-Pip-Arg-pNA (S-2238) acetate, a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA acetate is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA acetate is sensitive, accurate, and easy to perform .
    H-D-Phe-Pip-Arg-pNA acetate
  • HY-P0074
    GPRP
    3 Publications Verification

    Gly-Pro-Arg-Pro; Pefa 6003

    Thrombin Cardiovascular Disease
    GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .
    GPRP
  • HY-15701
    Leukadherin-1
    5+ Cited Publications

    Integrin Complement System Inflammation/Immunology
    Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling .
    Leukadherin-1
  • HY-125864B

    MMP Cadherin Cardiovascular Disease Neurological Disease
    Murine Fibrinogen is a native fibrinogen derived from mouse plasma. Murine Fibrinogen acts as a cerebrovascular permeability enhancer. Murine Fibrinogen activates matrix metalloproteinase-9 (MMP-9), downregulates the expression of vascular endothelial cadherin (VE-cadherin), and upregulates the expression of plasmalemmal vesicle-associated protein-1 (PV-1). Murine Fibrinogen increases macromolecular leakage from pial veins, thereby disrupting the microvascular integrity of cerebral blood vessels. Murine Fibrinogen can be used in studies related to cerebrovascular dysfunction .
    Murine Fibrinogen
  • HY-P0074A
    GPRP acetate
    3 Publications Verification

    Gly-Pro-Arg-Pro acetate; Pefa 6003 acetate

    Integrin Cardiovascular Disease
    GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .
    GPRP acetate
  • HY-15664
    Bivalirudin TFA
    Maximum Cited Publications
    9 Publications Verification

    Thrombin Interleukin Related RSV Infection Cardiovascular Disease Inflammation/Immunology
    Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .
    Bivalirudin TFA
  • HY-P5098

    Integrin Neurological Disease Cancer
    E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .
    E(c(RGDfK))2
  • HY-150229

    Liposome Cancer
    306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .
    306-N16B
  • HY-P1741
    Fibrinogen-Binding Peptide
    1 Publications Verification

    Thrombin Cardiovascular Disease
    Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .
    Fibrinogen-Binding Peptide
  • HY-125864C

    Biochemical Assay Reagents Cardiovascular Disease
    Porcine Fibrinogen is a coagulation protein, purified from porcine plasma with no plasminogen contained. Porcine Fibrinogen has excellent biocompatibility and does not induce aggregation of porcine platelets when in contact with porcine hepatocytes, aortic endothelial cells or hepatic sinusoidal endothelial cells. Porcine Fibrinogen is widely used in studies on the pathological mechanisms of cardiovascular diseases such as atherosclerosis and the development of related drugs .
    Porcine Fibrinogen
  • HY-P0308

    Drug Intermediate Cardiovascular Disease
    [Glu1]-Fibrinopeptide B is derived from fibrinopeptide B amino acid residues 1-14. Human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts.
    [Glu1]-Fibrinopeptide B
  • HY-N1400

    PKC Cardiovascular Disease
    (20R)-Ginsenoside Rh1 is the R-isomer of Ginsenoside Rh1 (HY-N0604), and it is found in red ginseng, ginseng, and other sources. (20R)-Ginsenoside Rh1 inhibits thrombin-induced conversion of fibrinogen to fibrin, exerting anticoagulant and antithrombotic effects .
    (20R)-Ginsenoside Rh1
  • HY-129056

    Thrombin NF-κB AP-1 Cardiovascular Disease Neurological Disease
    Melagatran is a reversible, selective, orally active direct inhibitor of thrombin with a Ki of 2 nM. Melagatran binds directly to the active site of thrombin, inhibiting thrombin-mediated conversion of fibrinogen to fibrin. Melagatran reduces the DNA binding activity of NF-κB and AP-1. Melagatran reduces fibrin deposition in organs, alleviates ischemic brain damage, and reduces the size of advanced atherosclerotic lesions. Melagatran can be used in the study of cardiovascular disease (coronary thrombosis, atherosclerosis) and ischemic brain damage .
    Melagatran
  • HY-E70231

    Others Cardiovascular Disease
    Thrombin-like enzyme is a proteolytic enzyme extraction of Agkistrodon halys venom. Thrombin-like enzyme can be used for degradation of fibrinogen. Thrombin-like enzyme can exacerbate myosin-induced EAM (experimental autoimmune myositis). Thrombin-like enzyme can be used for degradation of fibrinogen. Thrombin-like enzyme is commonly used for research of acute ischemic cerebrovascular disease, thromboangiitis obliterans, deep phlebitis and sudden deafness .
    Thrombin-like enzyme
  • HY-P10045

    Integrin Cardiovascular Disease
    Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .
    Integrin signaling inhibitor, mP13
  • HY-107966A

    Nadroparin calcium (MW 3600-5000)

    Thrombin Factor Xa Autophagy Bacterial Cardiovascular Disease Cancer
    Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .
    Heparin calcium (MW 3600-5000)
  • HY-P3726

    Integrin Inflammation/Immunology Cancer
    Lys-Gln-Ala-Gly-Asp-Val (KQAGDV) is the six most carboxyl-terminal amino acids in the fibrinogen γ-chain sequence. Lys-Gln-Ala-Gly-Asp-Val is a cell adhesion peptide which is mediated through the α2bβ3 integrin. Lys-Gln-Ala-Gly-Asp-Val is a potent adhesion ligand for smooth muscle cells (SMCs) .
    Lys-Gln-Ala-Gly-Asp-Val
  • HY-123275C

    S-2238 dihydrochloride

    Fluorescent Dye Others
    H-D-Phe-Pip-Arg-pNA (S-2238) dihydrochloride, a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA dihydrochloride is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA dihydrochloride is sensitive, accurate, and easy to perform .
    H-D-Phe-Pip-Arg-pNA dihydrochloride
  • HY-125864A

    Biochemical Assay Reagents Cardiovascular Disease
    Canine Fibrinogen is a native fibrinogen from canine plasma .
    Canine Fibrinogen
  • HY-125864D

    Interleukin Related NF-κB Cardiovascular Disease
    Rabbit Fibrinogen is a native fibrinogen from rabbit plasma. Fibrinogen is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
    Rabbit Fibrinogen
  • HY-P1507

    Integrin Cardiovascular Disease
    Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.
    Fibrinogen Binding Inhibitor Peptide
  • HY-NP167

    Biochemical Assay Reagents Others
    Fibrinogen from rat plasma can be used to prepare growth factor solutions.
    Fibrinogen from rat plasma
  • HY-148400

    TXC hydrochloride

    Ser/Thr Protease Drug Derivative Metabolic Disease
    Cetyl tranexamate (TXC) hydrochloride is an ester derivative of Tranexamic acid (HY-B0149). Cetyl tranexamate hydrochloride is an inhibitor of fibrinogen activation and can reduce the production of fibrinogen in keratinocytes induced by ultraviolet rays or damage, indirectly inhibiting the melanin production pathway. Cetyl tranexamate hydrochloride also targets melanin (dark spots) and hemoglobin (red spots), reducing vascular dilation and pigmentation by inhibiting inflammatory mediators (such as prostaglandins, platelet activating factors). Cetyl tranexamate hydrochloride can be used as a cosmetic ingredient and is suitable for epidermal pigment disorders such as photoaging, post-inflammatory hyperpigmentation (PIH), and melasma .
    Cetyl tranexamate hydrochloride
  • HY-123275

    S-2238

    Fluorescent Dye Others
    H-D-Phe-Pip-Arg-pNA (S-2238), a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA is sensitive, accurate, and easy to perform .
    H-D-Phe-Pip-Arg-pNA
  • HY-N0241

    Cholinesterase (ChE) Lipase Bacterial Cytochrome P450 Infection Metabolic Disease
    Rhodionin is an orally active, multifunctional antivirulence and cytoprotective agent that targets and inhibits Lipase, sortase A (SrtA), CYP2D6 (IC50=0.761 μM), AChE (IC50=2.43-57.5 μM), and DPPH free radicals (IC50=19.49 μM). Rhodionin is isolable from the roots of Rhodiola crenulata. Rhodionin reduces postprandial serum triglyceride levels in mice by inhibiting lipase activity. Rhodionin also binds directly to SrtA to inhibit its transpeptidase activity, thereby reducing the fibrinogen adhesion and surface protein A levels of MRSA, effectively inhibiting biofilm formation and protecting against MRSA-induced cell damage. Rhodionin improves the survival rate of infected mice without affecting MRSA growth, and finds wide application in studies related to hyperlipidemia, exogenous obesity, and pneumonia induced by methicillin-resistant Staphylococcus aureus (MRSA) .
    Rhodionin
  • HY-P1741A
    Fibrinogen-Binding Peptide TFA
    1 Publications Verification

    Integrin Cardiovascular Disease
    Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .
    Fibrinogen-Binding Peptide TFA
  • HY-P3537

    Amino Acid Derivatives Cardiovascular Disease
    AGDV is the γ chain of fibrinogen. AGDV is critical for platelet aggregation .
    AGDV
  • HY-121815

    Amyloid-β Neurological Disease
    TDI-2760 is an Aβ aggregation inhibitor with an IC50 of 1.67 μM. TDI-2760 can inhibit the Aβ-fibrinogen interaction and Aβ aggregation, and also modulate the contact system activation induced by Aβ42. TDI-2760 can be used in research related to vascular abnormalities and Aβ aggregation in Alzheimer's disease .
    TDI-2760
  • HY-P1493

    FPB,human

    Thrombin Inflammation/Immunology
    Fibrinopeptide B, human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin.
    Fibrinopeptide B, human
  • HY-120694

    RUC-2

    Integrin Cardiovascular Disease
    ML165 (RUC-2) is an aIIbb3 receptor antagonist. ML165 has orthosteric inhibition effect at the RGD binding domain. ML165 inhibits platelet adhesion to fibrinogen, and inhibits platelet aggregation (IC50: 96 nM) .
    ML165
  • HY-114164H
    Human α-Thrombin (Lyophilized)
    5+ Cited Publications

    Thrombin Cardiovascular Disease
    Human α-thrombin is a multifunctional serine protease that plays a pivotal role in the coagulation pathway. Human α-thrombin cleaves fibrinogen and converts it into fibrin. Human α-thrombin can stimulate platelet activation and stabilize fibrin polymers .
    Human α-Thrombin (Lyophilized)
  • HY-107966

    Nadroparin calcium (MW 15000-19000)

    Thrombin Factor Xa Autophagy Bacterial Cardiovascular Disease Cancer
    Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .
    Heparin calcium (MW 15000-19000)
  • HY-P991211

    STSP-0601

    Factor XI Cardiovascular Disease
    Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia .
    Bemiltenase alfa
  • HY-17369A

    L700462 hydrochloride; MK383 hydrochloride

    Integrin Cardiovascular Disease
    Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban hydrochloride
  • HY-17369BR

    L700462 (Standard); MK383 (Standard)

    Reference Standards Integrin Cardiovascular Disease
    Tirofiban (Standard) is the analytical standard of Tirofiban. This product is intended for research and analytical applications. Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban (Standard)
  • HY-P5767

    Integrin Cardiovascular Disease
    Fibrinogen γ-chain (117-133) is a selective intercellular adhesion molecule-1 (ICAM-1) inhibitor (IC50≈20-40 μg/mL). Fibrinogen γ-chain (117-133) blocks fibrinogen-mediated monocyte-endothelial adhesion. Fibrinogen γ-chain (117-133) is promising for research of thrombo-inflammatory diseases (e.g., atherosclerosis, organ transplant rejection) .
    Fibrinogen γ-chain (117-133)
  • HY-19163

    Integrin Cardiovascular Disease
    HY-19163 is an orally active fibrinogen receptor antagonist, with antiplatelet activities.
    SC-52012
  • HY-117824

    Integrin Others
    L-703014 is a fibrinogen receptor antagonist, with the IC50 of 94 nM, that acts as a novel parenteral and potential oral antithrombotic agent .
    L-703014
  • HY-123120

    Thrombin Others
    SA-152 is an organophosphorus inhibitor. SA-152 modulates the fibrinogen coagulation and TAME esterase activity of bovine α-thrombin .
    SA-152
  • HY-118410

    Integrin Cardiovascular Disease
    L-738167 is an orally active fibrogen receptor antagonist that prevents the binding of fibrinogen to GP IIb/IIIa. L-738167 can be utilized in thrombus research .
    L-738167
  • HY-169836

    Integrin Cardiovascular Disease
    Des-ethyl-carafiban (Compound 44) is a fibrinogen receptor antagonist that can effectively inhibit platelet aggregation induced by multiple agonists. Des-ethyl-carafiban can be used in the research of thrombotic diseases .
    Des-ethyl-carafiban
  • HY-142123

    Glucocorticoid Receptor Inflammation/Immunology
    Fluocortolone is an orally active anti-inflammatory agent that effectively reduces plasma fibrinogen levels. Fluocortolone inhibits Mycobacterium butyricum-induced foot edema in a rat model of adjuvanted joint inflammation (3-12 mg/kg) .
    Fluocortolone
  • HY-19275

    Integrin Cardiovascular Disease
    FR-158999 is a potent orally active fibrinogen inhibitor. FR-158999 exhibits potent anti-platelet activities with a pIC50 of 7.50. FR-158999 can be used for antithrombotic research .
    FR-158999
  • HY-10315

    RWJ-53308

    Integrin Cardiovascular Disease
    Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research .
    Elarofiban
  • HY-106932

    Integrin Cardiovascular Disease
    L-734217 is an orally active and potent fibrinogen receptor antagonist and an antithrombotic agent. L-734217 is excreted largely by the renal route and partly into the bile in dogs. L-734217 is promising for research of thrombotic disorders .
    L-734217

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: